Vinorelbine in Treating Patients With Metastatic Prostate Cancer
- Sponsor
- Swiss Cancer Institute
- Study ID
- NCT00003259
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- vinorelbine tartrate — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating patients with metastatic prostate cancer that has not responded to hormone therapy.
Key Dates
- Start date
- Oct 31, 1997
- Status verified
- Jun 2019
- Primary completion
- Sep 30, 1999
- Completion
- Sep 30, 1999
Study Design
- Enrollment
- 40 participants (estimated)
- Primary purpose
- TREATMENT
Related Studies
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Use of Tracking Devices to Locate Abnormalities During Invasive ProceduresEnrolling By Invitation · National Institutes of Health Clinical Center (CC) · Bethesda, Maryland
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate CancerRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey